Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. More Details
Adequate balance sheet with limited growth.
Share Price & News
How has Idorsia's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IDIA is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: IDIA's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: IDIA underperformed the Swiss Biotechs industry which returned 25.1% over the past year.
Return vs Market: IDIA underperformed the Swiss Market which returned 21% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Idorsia's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StCan You Imagine How Idorsia's (VTX:IDIA) Shareholders Feel About The 13% Share Price Increase?
1 month ago | Simply Wall StAnalysts' Revenue Estimates For Idorsia Ltd (VTX:IDIA) Are Surging Higher
2 months ago | Simply Wall StThe Idorsia Ltd (VTX:IDIA) Analysts Have Been Trimming Their Sales Forecasts
Is Idorsia undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IDIA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IDIA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IDIA is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: IDIA is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IDIA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IDIA is overvalued based on its PB Ratio (7.3x) compared to the CH Biotechs industry average (6.2x).
How is Idorsia forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDIA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IDIA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IDIA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IDIA's revenue (44.3% per year) is forecast to grow faster than the Swiss market (4.5% per year).
High Growth Revenue: IDIA's revenue (44.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IDIA is forecast to be unprofitable in 3 years.
How has Idorsia performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDIA is currently unprofitable.
Growing Profit Margin: IDIA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IDIA is unprofitable, and losses have increased over the past 5 years at a rate of 23.8% per year.
Accelerating Growth: Unable to compare IDIA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IDIA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5%).
Return on Equity
High ROE: IDIA has a negative Return on Equity (-76.03%), as it is currently unprofitable.
How is Idorsia's financial position?
Financial Position Analysis
Short Term Liabilities: IDIA's short term assets (CHF1.0B) exceed its short term liabilities (CHF127.5M).
Long Term Liabilities: IDIA's short term assets (CHF1.0B) exceed its long term liabilities (CHF722.4M).
Debt to Equity History and Analysis
Debt Level: IDIA's debt to equity ratio (100.3%) is considered high.
Reducing Debt: Insufficient data to determine if IDIA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IDIA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IDIA has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 31.3% each year.
What is Idorsia current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IDIA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IDIA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IDIA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IDIA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IDIA's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jean-Paul Clozel (65 yo)
Mr. Jean-Paul Clozel, M.D., co- founded Actelion Ltd (alternate name Actelion AG ) in 1997 and has been its Chief Executive Officer since 1999. Mr. Clozel serves as the Chief Executive Officer of Idorsia L...
Experienced Board: IDIA's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.1%.
Idorsia Ltd's company bio, employee growth, exchange listings and data sources
- Name: Idorsia Ltd
- Ticker: IDIA
- Exchange: SWX
- Founded: 2017
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF4.243b
- Shares outstanding: 166.91m
- Website: https://www.idorsia.com
Number of Employees
- Idorsia Ltd
- Hegenheimermattweg 91
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeuti...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/09 17:14|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.